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Being discovered long ago basophils have been neglected for more than a century. During the past decade evidence emerged that
basophils share features of innate and adaptive immunity. Nowadays, basophils are best known for their striking effector role in the
allergic reaction.They hence have been used for establishing new diagnostic tests and therapeutic approaches and for characterizing
natural and recombinant allergens as well as hypoallergens, which display lower or diminished IgE-binding activity. However, it
was a long way from discovery in 1879 until identification of their function in hypersensitivity reactions, including adverse drug
reactions. Starting with a historical background, this review highlights the modern view on basophil biology.
1. Introduction
Basophils are well known for their allergic effector function,
a feature applied in the basophil activation test. According to
current literature basophils are additionally conceived in the
center between the innate and adaptive immune responses [1,
2]. The following chapter intends to review the most impor-
tant findings during the past 150 years of basophil biology.
A Historical Perspective: from Discovery to Recognition as
Allergic Effector Cell. In 1879 Ehrlich discovered a cell
type with dark blue granula in peripheral blood stain-
ing experiments with basic dyes [3, 4], which he named
“basophilic granulocytes” or “basophils” according to their
unique appearance.He previously had described humanmast
cells in his doctoral thesis in 1878 [5], thus initially referred
to basophils as mast leucocytes or blood mast cells. Shortly
thereafter it was found out that they were leucocytes of
myeloid origin [6]. In 1894 and 1895, Kanthack and Hardy
continued to define the appearance and morphology of mast
cells and basophils [7]. They characterized the latter as “the
finely granular basophil cell” appearing solely in the blood
whichwas surprisingly accurate.Moreover, theywere the first
to describe basophils as very unstable and recognized their
“explosive nature,” in response to “certain chemical stimuli.”
This very basic understanding of basophil biology remained
state of knowledge for almost 60 years until the 1950s which
may have been due to their low abundance. A significant
role of basophils was questioned which pushed them into the
position of an “underdog” [8–11].
During this time, however, descriptions about hyper-
sensitivity reactions in patients emerged including research
efforts to elucidate their etiology. Portier and Richet were
the first mentioning the term anaphylaxis in 1902 when they
found out that dogs becamehypersensitive to anemone toxins
after repeated injections [12] and Pirquet et al. coined the
term “allergy” to describe the immune response in hyper-
sensitivity reactions [13–15]. With anaphylatoxin discovered
in the serum [16] and histamine shown to be involved in
smooth muscle contraction [17] different molecules were
proposed as key candidates responsible for such reactions.
The following two studies showed that anaphylaxis-triggering
molecules must be contained in the blood or serum: Ramirez
reported on a case of transmitted hypersensitivity in 1919
when a person got an asthmatic attack after receiving a blood
transfusion but had so far no history of hypersensitivity [18].
A similar discovery was made by Prausnitz and Ku¨stner in
1921 [19], when Ku¨stner, who was allergic to fish, locally
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transferred his allergy to Prausnitz’s skin. The molecules
responsible for the reaction, however, were not yet identified.
Further on prostaglandins and leukotrienes, slow-reacting
substances, with a late reaction onset, were discovered by von
Euler et al. in the 1930s [20, 21].
It was in 1934 that a delayed reaction in the skin after
repeated injection of a foreign protein was linked to basophils
and described as the so-called cutaneous basophil hyper-
sensitivity by Jones and Mote [22]. Five years later, Trager
described a similar basophil accumulation in the setting of a
tick bite and stated that basophils are crucial for the induction
of immune reactions. He claimed that the histamine-induced
itching was essential for the detection and removal of the tick
[23].
Despite these early reports it took almost 20 years until
discoveries in hypersensitivity were linked to basophils and
mast cells. It was in 1953 and 1955 when Riley et al. showed
that histaminewas stored predominantly in basophil granules
and suggested that these cells were involved in anaphylaxis
[24, 25]. Shelley and Juhlin were the ones who established a
test system for detecting histamine release from basophils;
the basophil activation test was born. The principle of the
first basophil activation tests was based on degranulation
monitoring using optical microscopy. Whole blood or leuko-
cytes (enriched by filtration) were subjected to activation
stimuli followed by rapid liquid fixation and staining with
basic dyes. Reduced levels of granular staining indicated
an activation-induced degranulation [26, 27]. Furthermore,
Juhlin and Shelley proved that histamine was released from
mast cells and basophils [28] by a radio immune assay which
was based on binding competition to an anti-histamine anti-
body between cell-derived histamine in the sample and 125l-
labeled histamine. The detailed degranulation mechanism of
basophils was finally explained when Ishizaka and Bennich
independently identified the serum factor responsible for this
immediate reaction in the years from 1966 to 1968 which they
agreed to call immunoglobulin (Ig) E.Their experimentswere
based on the Prausnitz-Ku¨stner reaction (for safety reasons
not recommended as involving intradermal serum transfer
from an atopic patient to a nonallergic control person) which
was blocked by antiserum from fractionated serum of allergic
individuals or by myeloma-derived IgE [29–31]. Some years
later Ishizaka et al. identified receptors for IgE on basophils
and mast cells. He described that binding of anti-IgE and
receptor aggregation led to the release of histamine from
these cells [32–34]. Soon after, Kulczycki Jr. et al. showed that
IgE was bound with high affinity, and Jarrett and Bazin found
out that helminthic parasite infection was the most powerful
inducer of IgE. They showed that rats infected with parasites
had a strong elevation in their total serum IgE levels [35, 36].
Measuring leukotrienes from supernatants of stimulated
basophils by radio immune-assay as alternative to histamine
release was pointed out by MacGlashan Jr. et al. in 1986
[37]. Basophil counting and activation monitoring by flow
cytometry finally came up in the 1990s when Knol et
al. started to utilize activation-induced and degranulation-
associated changes on the cell surface. They monitored the
appearance of CD63, alias Lamp-3, expressed in intracellular
granule membranes, with a fluorescence-labeled monoclonal
anti-CD63 detection antibody [38]. The CD63 molecule was
previously cloned and analyzed by Metzelaar et al. [39]. The
studies by Gibbs et al. in 1996 on IL-4 and IL-13 secretion
from basophils [40] were a furthermilestone for determining
the immunological capabilities of basophils. One year later,
the chemokine receptor, CCR3, was described to be highly
expressed on human blood basophils [41]. Bu¨hring et al.
added another important basophil-specific surface antigen
in 1999, when he discovered the ectoenzyme CD203c, a
versatile marker for basophil identification and activation
[42]. In the same year basogranulin was described for the
first time following the development and characterization of
a basophil-specific antibody, the anti-basogranulin antibody
BB1 [43]. Hirai et al. proposed another identification option
for basophils for flow cytometry by gating cells with low
side scattering which are prostaglandinDP2 receptor CRTH2
(CD294)-positive and CD3-negative [44]. Further activation
markers (CD13, CD107a, and CD164) were identified by
Hennersdorf et al. [45].
Summing up, during the last decades, our knowledge
on basophils drastically increased with the most relevant
findings depicted in the timeline of Figure 1. To date, these
new findings are utilized for basic and clinical research
questions related to gain a deeper insight into the biology
of basophils and to develop advanced diagnostic systems for
patients suffering from hypersensitivity reactions.
2. Basophil Development
Though mature basophils are extensively studied, the hem-
atopoietic origin of these cells is scarcely understood
[46]. As reviewed in detail elsewhere [47, 48], findings
in mouse blood cell hematopoiesis suggest basophils to
develop from hematopoietic stem cells (HSCs) via common
myeloid progenitors (CMPs), granulocyte-monocyte progen-
itors (GMPs), and (possibly) granulocyte progenitors (GPs)
in the bone marrow [47, 49]. Further development contin-
ues in the bone marrow (prebasophil mast cell progenitor,
pre-BMC) or in the spleen (basophil mast cell progenitor,
BMCPs) (Figure 2) [50, 51]. These cell types further differen-
tiate into basophil progenitors and mature basophils which
then are released into the blood stream.
During basophil hematopoiesis several transcription fac-
tors play crucial roles in determining the fate of the progen-
itors towards the fully differentiated basophil. Two central
factors in basophil development are the CCAAT enhancer-
binding protein alpha (C/EBP𝛼) and GATA binding protein
2 (GATA-2) [51, 52].TheGMP shows high C/EBP𝛼 levels and
almost no GATA-2. Upregulation of GATA-2 and simultane-
ous downregulation of C/EBP𝛼 directs cell development into
the basophil/mast cell progenitor (BMCP) line. Hence, the
BMCP has high GATA-2 and intermediate C/EBP𝛼 levels. A
further decrease of C/EBP𝛼 levels directs the cell fate towards
mast cell development. Upregulation of C/EBP𝛼 expression
in BMCPs triggers differentiation into basophil progenitors
which show high levels of both C/EBP𝛼 and GATA-2.
Several other transcription factors upstream of C/EBP𝛼
andGATA-2were described. Ikaros family zinc finger protein
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Figure 1: Timeline of discoveries during the evolution of basophil research.
1 (IKZF1) was shown to negatively regulate basophil devel-
opment by inhibition of C/EBP𝛼 expression [53], whereas
STAT5 was shown to enhance basophil development by
inducing C/EBP𝛼 and GATA-2 expression [50, 54]. Inter-
feron regulatory factor 8 (IRF8) was found to act upstream
of GATA-2 in Irf8 knockout mice showing reduced levels of
basophils. A further target of IRF8 is GATA1 which plays a
role in the generation of basophil progenitors and aids the
final differentiation step into basophils [55, 56].
Two more factors specifically prime basophils for dis-
tinct roles, namely, IL-3 and thymic stromal lymphopoietin
(TSLP). Short-term IL-3 treatment of bone marrow-derived
cells was shown to direct granulocyte-monocyte progenitors
into basophil differentiation. Basophils derived from such an
IL-3-induced lineage show high IgE reactivity and, therefore
are involved in IgE-mediated acquired immunity [57]. In
contrast, basophils derived from progenitors treated with
TSLP showed lower responsiveness to IgE/antigen complexes
but displayed features of a chronic inflammatory cell response
including higher IL-18 and IL-33 receptor expression. These
cells are predominantly involved in innate immunity. The
balance between basophils derived from either IL-3 or TSLP
thus is considered crucial for the type of mediator response
[58].
3. The Basophil in the Immune Network
Basophil biology and the basophils’ interplay with other
cells are essentially directed by cytokines, chemokines, and
other soluble mediators. In the following chapters important
molecules involved in different ways of basophil activation
and effector functions, basophil adhesion, migration, and
survival, and the dual role of basophils in protection against
parasites versus pathogenicity are described. An overview of
the most relevant surface molecules and secreted substances
is shown in Figure 3.
3.1. Basophil Activation. Basophils are best known for their
effector function triggered by the release of mediators upon
activation. This activation can be mediated by a large num-
ber of different molecules such as immunoglobulins, cyto-
/chemokines, factors of the complement system, growth
factors, bacteria-derived ligands, and proteases interacting
with surface receptors (Table 1). The subsequent intracellular
signaling pathway leads to release of preformed molecules
such as histamine and leukotriene C4 (LTC4), chemotactic
factors like the platelet activation factor (PAF) and retinoic
acid, basogranulin, cytokines including IL-4, IL-13, IL-6,
TNF𝛼, and TSLP, chemokines, and antimicrobial peptides.
They are all involved in immediate and late-phase reactions
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Figure 2: Influence of C/EBP𝛼 andGATA-2 on the basophil development in spleen (left) and bonemarrow (right). In the finalmaturation step
basophilsmight be either elicited by IL-3 or TSLP.HSC: hematopoietic stem cell; CLP: common lymphoid progenitor; CMP: commonmyeloid
progenitor; GMP: granulocyte/monocyte progenitor; BMCP: basophil/mast cell progenitor; pre-BMP: prebasophil mast cell progenitor; BaP:
basophil progenitor; IL-3: interleukin 3; TSLP: thymic stromal lymphopoietin.
of the immune system and symptoms observed in allergic
reactions [59, 60].
3.1.1. Activation by Immunoglobulins
IgE. IgE/antigen complexes mediate the cross-linking of
high affinity IgE receptors Fc𝜀RI on the basophils’ surface
by downstream signaling of the Src family kinases Fyn,
Lyn, and Syk, with activation of the PI3-kinase and the
MEK/ERK pathways (Figure 4). It is the most popular and
extensively investigated activating mechanism of basophils
[61, 62]. As a consequence, intracellular granules fuse with
the cell membrane and preformed mediators [63, 64] are
released, and granulemembranemolecules like CD11b, CD13,
CD63, CD107a, CD107b, CD203c, CD200R, CD300a, and the
vascular endothelial growth factor A (VEGF-A) [65–67] are
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Figure 3: Surfacemolecules (boxes) and secretedmediators (arrows) of human basophils. BAFF, B cell-activating factor; CxaR, anaphylatoxin
receptors; CCL/CXCL, chemokine ligands; CCR, CXCR, chemokine receptors; CD, cluster of differentiation; CRTH2, chemoattractant
receptor-homologous molecule expressed on TH2 cells; FcxR, immunoglobulin receptors; FPR, formyl peptide receptors; GM-CSFR,
granulocyte macrophage colony-stimulating factor receptor; IL, interleukin; IL-R, interleukin receptor; LepR, leptin receptor; LIR, leukocyte
immunoglobulin-like receptor; LTC4, leukotriene C4; MMP-9, matrix metallopeptidase; NOD2, nucleotide-binding oligomerization
domain-containing protein 2; PAF, platelet activating factor; SDF-1, stromal cell-derived factor 1; ST2, growth stimulation expressed gene
2; TLR, toll-like receptors; TNF𝛼, tumor necrosis factor alpha; TRAIL-R, tumor necrosis factor-related apoptosis-inducing ligand receptor;
Trk-A, tropomyosin receptor kinase A; TSLP, thymic stromal lymphopoietin; TSLPR, thymic stromal lymphopoietin receptor; VEGF-A,
vascular endothelial growth factor A.
translocated to the outer cell surface, the so-called anaphy-
lactic degranulation. Subsequently, mediators like LTC4 are
synthesized de novo and secreted. During basophil degranu-
lation the two important Th2 response-driving cytokines IL-
4 and IL-13 are secreted. The IL-4 secretion is an immediate
response with preformed but also newly synthesized (stored
RNA) IL-4, whereas IL-13 secretion occurs after several
hours of basophil stimulation. IL-4 plays a crucial role in
triggering Th2 cell differentiation from na¨ıve CD4+ T cells
and suppresses the harmful Th1 responses [40, 68, 69].
Basophil-derived IL-4 together with IL-6 activates B cells
in humoral protective pathogen responses by enhancing
their proliferation and immunoglobulin production [70].
Basophil-derived IL-4 also contributes to the upregulation of
the C-C chemokine ligand (CCL)11 in fibroblasts, enhancing
eosinophil migration [71], to the differentiation ofmonocytes
into M2 macrophages, and to the proliferation and IL-5
production of group 2 innate lymphoid cells [72, 73].
IgD. IgD binds to a so far not further described calcium-
mobilizing receptor on basophils and, upon receptor cross-
linking, induces antimicrobial, opsonizing, proinflammatory,
B cell-stimulatory, and Th2-driving programs, for example,
by upregulation of IL-4, IL-13, B cell-activating factor (BAFF),
proliferation-inducing ligand (APRIL), CXCL8,CXCL10, and
cathelicidin, but has no influence on histamine release [74].
Secretory IgA. Secretory IgA was shown to provoke basophil
activation by histamine and LTC4 release experiments. Acti-
vation of the cells was solely observed upon stimulating IL-
3 primed basophils with sepharose-immobilized secretory
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Table 1: Stimulation of basophils by different mediators.
Immunoglobulins
Cyto-/chemokines
complement
growth factors
Bacteria-derived
products
IgE IL-3 fMLF
IgD TSLP Muramyl dipeptide
sIgA IL-25 TLR ligands
IgG IL-33 Proteases
IL-18
CXCL8/IL-8
Complement
IL-5
GM-CSF
NGF
LIR7
Ig, immunoglobulin; sIg, secretory Ig; IL, interleukin; TSLP, thymic
stromal lymphopoietin; CXCL, chemokine ligand; GM-CSF, granulocyte
macrophage colony-stimulating factor receptor; NGF, nerve growth factor;
LIR, leukocyte immunoglobulin-like receptor; fMLF, formyl-methionine-
phenylalanine; TLR, toll-like receptor.
IgA [75]. The effect was potentiated when secretory IgA was
immobilized on plastic plates instead of sepharose beads [76].
IgG. Basophils express the IgG receptors Fc𝛾RIIA, Fc𝛾RIIB,
and Fc𝛾RIIIB [77–79]. Interestingly, the activating Fc𝛾RIIA
receptor is present only in minute amounts, whereas the
inhibitory Fc𝛾RIIB receptor is expressed in much higher
quantity. Stimulation of basophils with IgG immune com-
plexes, however, did not lead to their activation. Instead, an
IgE-mediated response was dampened by IgG binding and
this effect was even potentiated in IL-3 primed cells. This
dampening effect could be a reason for symptom reduction
during immunotherapy in which increased levels of allergen-
specific IgG occur [80].
3.1.2. Activation by Cyto-/Chemokines, Complement,
and Growth Factors
IL-3. IL-3 was described as a key molecule in prim-
ing/activation of basophils. It is crucial for cytokine produc-
tion, especially of IL-4 and IL-13 following IgE-dependent
stimulation, the expression of cell surface antigens, such as
CD203c and IL-1 receptor-like 1 (IL1RL1, alias ST2), and
releasability of cells [81–83]. Basophils themselves release IL-
3 during the late-phase response to antigens, thus, apparently
creating a positive feedback loop in activation [84–86].
Furthermore, IL-3 is crucial for the expansion of
basophils and an enhanced response in parasitic infection
[87, 88]. Signaling through the IL-3 receptor is very similar
to IgE receptor signaling and comprises the PI3-kinase/Akt/
mTOR, the MEK/ERK, and the JAK/STAT pathway [65].The
overall importance and versatility of IL-3 in basophil biology
will be elaborated further in the following chapters of this
review.
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Ras
Raf
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Figure 4: Scheme of basophil activation via Fc𝜀RI cross-linking
and the involved signaling pathways leading to mediator release.
Basophil-derived IL-4 and IL-13 triggerTh2 responses and enhance
immunoglobulin production from B cells. DAG, diacylglycerol;
ERK, extracellular signal-regulated kinase; Fc𝜀RI, high affinity IgE
receptor 1; Fyn, src-related proto-oncogene; IgE, immunoglobulin
E; IL, interleukin; IP3, inositol trisphosphate; LTC4, leukotriene
C4; Lyn, Lck/Yes novel tyrosine kinase; PI3K, phosphoinositide 3-
kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein
kinase C; PLC, phospholipase C; MEK, MAPK/ERK Kinase; Raf,
rapidly accelerated fibrosarcoma; Ras, rat sarcoma; S1P, sphingosine-
1-phosphate; SK, sphingosine kinase 1; Syk, spleen associated tyro-
sine kinase.
TSLP. Incubation of basophils with thymic stromal lym-
phopoietin (TSLP) leads to a significant increase of his-
tamine, IL-4, and IL-13 and CD203c upregulation. TSLP thus
is an activation enhancer of human basophils. Neutralizing
antibodies against the TSLP receptor prevent basophils from
releasing IL-4 and IL-13 and inhibit CD203c upregulation.
Moreover, activation by TSLP depends on an IL-3 receptor
component, hence, on the IL-3-specific activation pathway,
contributing to IL-3 production of basophils and high surface
expression of CCR3 [89].
IL-25 and IL-33. During infection with parasites, viruses, or
exposure to allergens, alarmin cytokines like IL-33 and IL-
25 are important initiators of Th2 responses [90]. Human
basophils express receptors for IL-25 (IL-17RB) and IL-33
(ST2) and priming of the cells with IL-3 as well as IgE-
mediated activation upregulates receptor expression [91–94].
Basophils stimulated with IL-33 activate the NF𝜅B and p38
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MAP-kinase pathways and secrete type 2 cytokines (IL-4, IL-
5, IL-6, IL-9, and IL-13). BothCD203c and IL-3 receptor alpha
expressions were upregulated upon activation of IL-25 or IL-
33 [91, 92, 94, 95]. Besides, basophils secrete IL-25 upon IgE
challenge [96] and IL-33 is able to upregulate the expression
of leptin receptors on the basophil surface which can induce
degranulation and cytokine synthesis [97].
IL-18. Although human basophils express the receptor for
IL-18, a stimulation capability of this cytokine could not be
observed in humans [98].
CXCL8/IL-8. CXCL8/IL-8 activates basophils by binding to
its receptor on the cell surface in an IgE-independentmanner
and independent of pretreatment with IL-3. This was shown
by Krieger et al. who measured the transient rise of cytosolic
free calcium concentrations after activation of basophils by
IL-8 [99].
Complement. Various other natural ligands promote basophil
activation including the complement products C5a and C3a
and the chemokines CCL2, CCL3, or CCL5.The complement
products C3a and C5a, also called anaphylatoxins, have the
ability to induce histamine and LTC4 release from human
basophils. IL-3 is necessary forC3a-mediated but not forC5a-
mediated histamine release, whereas LTC4 only is released
in combination with IL-3 [100]. Activation of basophils with
the combination of C5a and IL-3 is also able to stimulate the
release of IL-4 and IL-13 [101]. The signaling pathway of C3a
and C5a is initiated by G-protein-coupled receptors (GPCRs)
which are also involved in the basophil activation via CCL2,
CCL3, and CCL5 [102, 103].
IL-5 and GM-CSF. IL-5 and granulocyte macrophage colony-
stimulating factor (GM-CSF) have been shown to contribute
to basophil activation in combination with other agonists
which induce histamine and LTC4 release suggesting syn-
ergistic effects. GM-CSF has a higher potency to add to
histamine release compared to IL-5, whereas LTC4 produc-
tion is more affected by IL-5. The underlying mechanisms
relate to IL-5, rendering basophils more responsive to the
anaphylatoxin C5a [104] and GM-CSF, rendering basophils
more sensitive to the anaphylatoxin C3a [105]. Signaling of
GM-CSF and IL-5 is very similar to that of IL-3 as they share
the common signal-transducing beta-chain [106–108].
NGF. Human basophils even can be coactivated by nerve
growth factor (NGF) as they have tyrosine protein kinase
receptors (Trk) A on their cell surface. Together with IL-5,
NGF can prime basophils to release LTC4 [109] and NGF can
directly stimulate IL-13 secretion in human basophils [110].
Gibbs et al. investigated the effects of IL-3 and NGF on the
release of histamine, IL-4, and IL-13 from human basophils
and found that both had the same potential in enhancing
histamine and IL-13 release and, to a lower extent, the IL-4
release in basophils primarily activated in an IgE-dependent
way. In addition, high levels of NGF induced cytokine release
from basophils via an IgE-independent route [111].
LIR7. Another receptor expressed on the surface of human
basophils is leukocyte immunoglobulin-like receptor (LIR) 7
which is coupled to the common Fc receptor gamma chain.
Monoclonal antibody-based receptor cross-linking induced
the release of histamine, LTC4, and IL-4 [112].
3.1.3. Activation by Bacteria-Derived Products
Formyl-Methionine-Phenylalanine (fMLF). fMLF is an N-
formylated tripeptide that is derived from gram-negative
bacteria. It is a potent chemotactic factor for leukocytes
that have the formyl peptide receptor (FPR)-1, which is
the most prominent one of this receptor family, on their
surface [113]. Basophils express FPR-1, 2, and 3, of which
FPR-1 binds fMLF with high affinity, whereas FPR-2 is a
low affinity receptor for fMLF. Upon stimulation of the cells
with fMLF a signal cascade is triggered involving receptor
phosphorylation, which inhibits further activation of the
same receptor.Thephosphorylation signal induces the release
of proinflammatorymediators and triggers chemotaxis. FPR-
2 and FPR-3 are mainly involved in chemotaxis to pathogen-
derived molecules, for example, the Helicobacter pylori-
derived peptide Hp2–20 [114].
Muramyl Dipeptide. Recently, the intracellular pattern recog-
nition receptor nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) was identified in the cytosol of
basophils [115]. NOD2 is the receptor for muramyl dipeptide,
a specific structure of bacterial peptidoglycans [116]. Hence,
the route via NOD-like receptors (NLRs) may constitute
another avenue for activation by bacterial substances.
TLR Ligands. Pathogens from bacteria, viruses, and fungi are
recognized by immune cells via toll-like receptors (TLRs)
located on the cell surface or within cellular endosomes.
So far, 13 different TLRs have been identified. TLR1, 2,
4, 5, 6, 9, and 10 mRNA and/or protein expression was
identified in human basophils [117–123]. Basophils reacted
to TLR2 stimulation with peptidoglycan by secreting the
cytokines IL-4 and IL-13 but neither histamine nor LTC4
were released [118]. High concentrations of LPS, ligand for
TLR4, enhanced CD63 surface expression and histamine
release from basophils of atopic patients in combination
with allergen stimulation [120]. Stimulating basophils with
the TLR5 ligand flagellin enhanced IL-6 secretion from the
basophils [123]. Simultaneous stimulation of the high affinity
IgE receptor and TLR4 or TLR9 synergistically upregulated
IL-4, CXCL8, IL-13, and CCL5 secretion [124]. Moreover,
an elevated CXCL8 secretion was observed in allergic indi-
viduals upon TLR1/2 and TLR2/6 stimulation [122]. These
findings suggest a connection between the pathogen-induced
basophil activation and an allergic response of basophils.
3.1.4. Activation by Proteases. Basophils may react to pro-
teases via direct sensing of the protease activity. This circum-
stance earns special attention as some of the most common
allergens are proteases. One famous candidate is the house
dust mite allergen Der p 1 which was able to induce IL-
4, IL-5, and IL-13 production from basophils independently
from the presence or absence of IgE [125]. However, signaling
comprises similar activation pathways compared to IgE-
mediated activation. This was confirmed by a study using
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bone marrow-derived murine basophils which, upon direct
activation by the cysteine protease papain, produced theTh2-
inducing cytokines IL-4, IL-6, and TNF𝛼 via PI3-kinase and
ERK pathways [68]. Pretreatment of such protease antigens
with protease inhibitors diminished their ability to activate
basophils [125].
3.2. Basophil Adhesion and Migration
3.2.1. Adhesion. In addition to its versatile roles in all kinds
of basophil responses, IL-3 also induces integrin CD11b
expression and therefore is involved in the adhesion of
basophils to vascular endothelial cells. GM-CSF and IL-
5 share similar properties in basophil adhesion, however,
with lower potential to induce integrin CD11b expression
[126, 127]. Stimulation of the cells with IL-33 induced CD11b
expression on basophils and enhanced eotaxin (CCL11)-
directed chemotaxis via the basophil surface receptor CCR3
[128]. Moreover, P-selectin, CD49d, CD49e, CD49f, and
CCR7 all have been identified on the basophil surface and
are involved in the IL-3-mediated rolling and adhesion of
basophils to endothelial cells [129].
3.2.2. Migration. Upon adherence of the basophils to the
cells of the vessel walls they first have to transmigrate across
the endothelial cell layer followed by breaking through the
basement membrane (transbasement membrane migration,
TBMM) to reach the site of inflammation. Transendothelial
migration (TEM) of basophils was mediated and directed
mainly by eotaxin, the chemokine ligand of CCR3, andCCL5,
the chemokine ligand of both CCR1 and CCR3, in freshly
isolated cells. Differently, in basophils cultured for 24 hours
SDF-1 induced strong migration responses via binding to
CXCR4 on the basophil surface. Interestingly, IL-3 again
has an additive effect in eotaxin-mediated TEM. Adhesion
molecules involved in TEM of basophils are the 𝛽2 integrins
leukocyte function antigen-1 (LFA, alias alpha-L/beta-2, or
CD11a/CD18) and macrophage-1 antigen (Mac-1, alias alpha-
M/beta-2, or CD11b/CD18), and the 𝛽1 integrin very late
antigen 4 (VLA-4, alias alpha-4/beta-1, or CD49d/CD29).
Eotaxin- or IL-3-stimulated basophils showed TEM which
was mainly depending on the 𝛽1 integrins and their endothe-
lial ligand VCAM-1 [130–133].
In contrast to TEM, chemokines had no effect on TBMM
of resting basophils. However, in presence of IL-3, CXCL8
(via CXCR1) and CCL5 (via CCR1 and CCR3) were able
to induce TBMM [134]. The same was observed with the
lipid mediators 5-oxo-eicosatetraenoic acid and PAF. IL-3
presumably positively affects the expression of the 𝛽2 integrin
and surface matrix metalloproteinase MMP-9 which coop-
eratively help basophils to cross the basement membrane
[130, 131, 134].
Interestingly, basophils migrated upon IgE stimulation
and Fc𝜀RI cross-linking. This migratory effect was even
observed at minimum amounts of stimulant without trig-
gering basophil degranulation and histamine release. The
same effect was observed upon activation with Der f 2 in
Dermatophagoides farinae-allergic donors [135].
3.3. Basophil Survival and Apoptosis. The foremost known
cytokine prolonging basophil survival is IL-3. In trypan blue
staining experiments, this cytokine was reported to prolong
the lifespan of cultured basophils from maximum three days
up to several weeks [136]. The survival-prolonging effect was
observed even at minute amounts of IL-3 and shown to be
muchmore potent than IL-5 or GM-CSF, two other cytokines
with effect on basophil survival [127]. Moreover, stem cell
factor (SCF) was shown to boost the survival effects of IL-3
[137] and also IL-25 binding to its receptor inhibits basophil
apoptosis as measured by annexin V staining [91].
In contrast, human basophils express the death recep-
tors CD95, tumor necrosis factor-related apoptosis-inducing
ligand receptors (TRAIL-R)1, and TRAIL-R2 and treatment
with an anti-CD95 antibody significantly increased apoptosis
in basophils [98, 138]. Glucocorticoids, too, were shown to
induce apoptosis in basophils and this apoptotic effect is
considered responsible for their anti-inflammatory proper-
ties [139]. Antiallergic and antiasthmatic drugs also have
apoptotic effects on basophils, as shown by olopatadine and
theophylline treatment of purified human basophils. Besides,
their apoptotic capacity even overruled survival prolonging
effects of low doses of IL-3 [140].
3.4. Basophils as Antigen-Presenting Cells? Anumber of stud-
ies performed on mouse basophils came to the conclusion
that basophils are potent antigen-presenting cells. Soon after,
doubts arose as others could not confirm the postulated
antigen-presenting role in birch pollen-allergic patients. In
coculture experiments of T cells with APCs but not with
basophils T cell proliferation was determined upon allergen
treatment [141] and fluorescence-labeled Bet v 1, used to
detect internalization of allergen by basophils, was neither
internalized, processed, nor presented [142]. The antigen-
presenting effects observed in the original publication most
likely were due to contamination of purified basophils with
dendritic cells [143].
3.5. Protective Functions of Basophils
3.5.1. Ectoparasites. Starting from the above-mentioned
experiments with ticks performed by Trager [23] in the late
1930s, it was later shown that hosts can develop resistance to
ticks by impairing engorgement and reducing viability of the
parasite [144]. Infiltration of basophils to the feeding site was
observed in guinea pigs and mice, and considered essential
for tick resistance, as it was reduced upon basophil ablation
[145, 146].
Basophils have also been shown to infiltrate sites infected
by Sarcoptes scabiei (scabies) mites. A protective role of
basophils against thesemites has been deduced from a patient
lacking eosinophils and basophils who was suffering from an
extensive scabies manifestation [147, 148].
3.5.2. Helminths. Typically, helminth infection induces acti-
vation of Th2 cells, eosinophils, basophils, mast cells, and
type 2 innate lymphoid cells plus high serum IgE levels [149].
Severalmousemodels have been developed inwhich the roles
of basophils in helminth infections were studied. Infection
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with the nematode Nippostrongylus brasiliensis induced sen-
sitization of basophils which prevented secondary infection
in mast cell-depleted mice [150, 151]. Another study showed
that trapping of N. brasiliensis larvae in the skin depends
on basophils which activated M2 macrophages by secreting
IL-4. Migration of the larvae to the lung and intestine thus
was impeded [152]. Adult N. brasiliensis worms were actively
expelled presumably upon IgE-mediated receptor cross-
linking of basophils and downstream IL-4/IL-13-dependent
mechanisms [153].
A strong basophil-induced Th2 response resulted in
the formation of granulomas absorbing toxic egg products
and prevented surrounding tissue damage in Schistosoma
mansoni infection [149]. In this case basophils were acti-
vated by IL-4-inducing principle of Schistosoma eggs/𝛼1
(IPSE/𝛼1). This major immunogenic trematode egg glyco-
protein induces IL-4 secretion from basophils by binding
nonspecifically to cell-bound IgE [154].
3.5.3. Parasitic Protozoa. The role of basophils in infections
by protozoa like Leishmania, Toxoplasma, Trypanosoma, or
Plasmodium (malaria) is scarcely investigated. Plasmodia
were shown to induce increased levels of histamine in the
serum of infected patients [155] but elevated basophil counts
were not observed [156]. In severe malaria cases basophil
responsiveness, as determined by CD203c upregulation, was
increased compared to mild infections [157]. In mouse
studies high basophil counts protected from cerebral malaria
and increased CD41 surface expression indicated basophil
activation [149, 158, 159].
3.5.4. Respiratory Bacteria. Basophils were postulated to
contribute to antibacterial defense in the upper respiratory
tract of Haemophilus influenzae- and Moraxella catarrhalis-
infected patients via an IgD-dependent mechanism. Mon-
oclonal IgD bound to beads was used to stimulate the
release of proinflammatory and antimicrobial mediators
from basophils of healthy donors, and the resulting super-
natant prevented microbe replication [74, 160].
3.6. Basophils and Disease
3.6.1. Hypersensitivity. Basophils are best known for their
role in eliciting hypersensitivity reactions including imme-
diate, late-phase, and delayed hypersensitivity reactions.
Allergen cross-linking leads to release of histamine, LTC4,
and PAF, key molecules of the immediate type reaction
leading to typical signs of allergy ranging from itch to the
life-threatening anaphylaxis [161]. Six to 12 hours after the
immediate response, late-phase reactions like allergic rhinitis
and asthma occur. Basophils infiltrate the affected tissues
and through IL-4 secretion promote aTh2 environment [162,
163]. Also in delayed hypersensitivity reactions basophils are
suggested to play a pivotal role in sustaining a Th2 milieu
through IL-4 and IL-13 release [161, 164].
3.6.2. Autoimmunity. Basophils may contribute to the devel-
opment of lupus nephritis as patients showed higher basophil
responsiveness than controls determined by CD203c upreg-
ulation. Concomitantly, serum levels of autoreactive anti-
nuclear IgE correlated with disease severity. Using Lyn−/−
lupus nephritis mice, autoreactive IgE-activated basophils
promoted a Th2 environment which led to disease aggrava-
tion via enhanced autoantibody production [165, 166].
3.6.3. Malignancy. Increased numbers of basophils have
been observed in acute and chronic myeloid leukemia, and
basophilia was associated with a reduced overall survival in
patients with myelodysplastic syndromes [167–169].
4. Basophil Activation Test
Thebasophil activation test or BAT is an in vitromethod used
to diagnose hypersensitivity reactions of patients. In BAT
the basophils are identified by flow cytometry via distinct
basophil surface molecules like CCR3, recently determined
as one of the most robust basophil identification methods
[170]. Other identification strategies use anti-CD123+/HLA-
DR- or anti-CRTH2+/anti-CD3-, as mentioned above, or
staining of IgE bound to Fc𝜀RI on the basophil surface [171].
Latter method, however, might potentially interfere with the
activation pathway of the cells.
Next to identification, basophil activation can be mea-
sured via CD63 or CD203c upregulation. CD203c is a
highly specific basophil molecule [172]. Both molecules are
upregulated upon cross-linking of the Fc𝜀RI by allergen-
IgE complexes and therefore used to detect the activation
of donor basophils upon allergen stimulation in clinical
diagnosis by BAT [173]. As reviewed by Hoffmann et al.
[174, 175] BAT is successfully used to diagnose IgE-mediated
allergies, for example, in food, hymenoptera venom, latex,
and inhalant allergies. A more distinct view has to be drawn
when analyzing allergies/hypersensitivities to drugs (DHRs).
Suitability of BAT as a biomarker for diagnosis of immediate
DHRs has been evaluated recently as a safe and, at least for
some DHRs, reliable method. However, provocation testing
is still of uttermost importance in clinical evaluation [176].
4.1. Basophil Activation Test as a Tool for Characterization
of Hypoallergens. In a number of reports basophils derived
from allergic donors have been used for characterization of
recombinant hypoallergens in the format of BAT using the
activationmarkersCD63orCD203c [177–185].Thedecreased
allergenic capacities of the hypoallergens have been evaluated
in different ways though. One reliable way of calculating the
hypoallergenic factor with good reproducibility is depicted in
Figure 5. The hypoallergenic factor can be determined in an
analytical way from the ratio of the concentrations of half-
maximal basophil activation (C50 values) of allergen versus
hypoallergen, which can be achieved by approximating the
experimentally determined activation values to a sigmoidal
curve using, for example, the Solver add-in of Microsoft
Excel based on the following formula: 𝑦 = bottom + (top
− bottom)/(1 + (𝑥/C50)−slope) [178].
An alternative approach for characterizing recombinant
allergens [186, 187], hypoallergens [178, 188], allergenic
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Figure 5: Determination of the hypoallergenic factor (here of 122)
fromC50 values of allergen (20.1 pg/mL, in red) versus hypoallergen
(2.46 ng/mL, in blue). The experimentally determined activation
values (⧫) have been approximated to analytically defined sigmoidal
curves (broken lines) from which the C50 values were calculated
[178].
extracts [178], and other allergy-related research purposes
including the investigation of drug hypersensitivity reactions
[189, 190] has been pursued by the use of “humanized” rat
basophil leukemic cells, that were established about a decade
ago and express the human high affinity IgE receptor chains
[191].
5. Concluding Remarks
Even though they have been first described long ago, human
basophils have just recently undergone an amazing devel-
opment in the investigation of the functional roles in the
context of the human immune system. Panels of cyto-
/chemokines secreted and receptors expressed have been
described. Moreover, an extensive array of other molecules
including immunoglobulins, cyto-/chemokines, factors of
the complement system, bacterial compounds, and growth
factors have been shown to influence the activation state of
basophils. A rise from being conceived as “underdogs” [192],
shortly hyped as antigen-presenting cells, currently arrived
at a solid and well-established role in allergy diagnosis [174]
characterized the evolution of human basophils’ biology.
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